Raleigh-based Focal Medical, an oncology device company that received early funding from the North Carolina Biotechnology Center, has been acquired by a Florida biopharmaceutical company. Financial ...

After several days of fielding criticism about the move behind the scenes, Gov. Maura Healey on Friday named the state's top ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Governor Maura Healey on Friday named four new members to the restructured state agency charged with keeping health care ...

The commercial license will become effective upon completion of the transition of commercial rights from Biogen back to ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

EMA's CHMP backs key drugs from KalVista, Biogen & Ionis for conditions like hereditary angioedema & postpartum depression.

Biogen said a key European regulatory committee has recommended approval of its Zurzuvae treatment for women with postpartum depression. Biogen on Friday said a green light would make Zurzuvae the ...

Biogen is ramping up in RTP with a fresh $2 billion investment. © 2025 American City Business Journals. All rights reserved.

The CHMP’s recommendation for ZURZUVAE will now be reviewed by the EC for marketing authorization in the European Union with a final decision expected in the third quarter of 2025. The U.S. FDA ...

The Tintina fault has triggered many more earthquakes than was thought — and a build-up of strain poses a hazard.

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...